Johnson & Johnson (JNJ) reported their Q4 earnings and revenue numbers which exceeded market estimates, reporting EPS of $1.86 per share versus $1.82 expected and revenue of $22.48 billion versus $21.67 billion expected.
The company’s pharmaceutical unit, also working on a coronavirus vaccine, reported $12.26 billion in revenue, a 16% year-over-year increase as demand for its prescription drugs rose. Its consumer unit, involved in products such as Listerine, generated $3.6 billion in revenue, up from 1.4% from a year earlier. Its medical device unit reported $6.58 billion, a 0.7% decrease. Johnson & Johnson forecasted an adjusted profit for 2021 of $9.40 to $9.60 per share and sales ranging from $90.5 billion to $91.7 billion.
The healthcare giant is expected to release data from its phase three trial testing its Covid-19 vaccine as early as this week.
“I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs,” “We continue to progress our COVID-19 vaccine candidate and look forward to sharing details from our Phase 3 study soon.” stated CEO Alex Gorsky.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.
